{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:34:12Z","timestamp":1740123252486,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T00:00:00Z","timestamp":1512000000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007231","name":"Cancerf\u00f6reningen i Stockholm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007231","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007230","name":"Stiftelsen Konung Gustaf V:s Jubileumsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008594","name":"Linn\u00e9a och Josef Carlssons Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008594","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BRECT"},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s10549-017-4599-4","type":"journal-article","created":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T00:50:40Z","timestamp":1512003040000},"page":"349-355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer"],"prefix":"10.1007","volume":"168","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4122-9624","authenticated-orcid":false,"given":"Alexios","family":"Matikas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Margolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"Hellstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemming","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils-Olof","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Edlund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet","family":"Lidbrink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbro","family":"Linderholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Lindman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Malmstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Villman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodoros","family":"Foukakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,30]]},"reference":[{"issue":"9814","key":"4599_CR1","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","volume":"379","author":"R Peto","year":"2012","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group, Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432\u2013444. \n                        https:\/\/doi.org\/10.1016\/S0140-6736(11)61625-5","journal-title":"Lancet"},{"issue":"6","key":"4599_CR2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","volume":"21","author":"IC Henderson","year":"2003","unstructured":"Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6):976\u2013983","journal-title":"J Clin Oncol"},{"issue":"5","key":"4599_CR3","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.1997.15.5.1858","volume":"15","author":"B Fisher","year":"1997","unstructured":"Fisher B, Anderson S, Wickerham DL, DeCillis A, Dimitrov N, Mamounas E, Wolmark N, Pugh R, Atkins JN, Meyers FJ, Abramson N, Wolter J, Bornstein RS, Levy L, Romond EH, Caggiano V, Grimaldi M, Jochimsen P, Deckers P (1997) Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15(5):1858\u20131869","journal-title":"J Clin Oncol"},{"issue":"11","key":"4599_CR4","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.1999.17.11.3374","volume":"17","author":"B Fisher","year":"1999","unstructured":"Fisher B, Anderson S, DeCillis A, Dimitrov N, Atkins JN, Fehrenbacher L, Henry PH, Romond EH, Lanier KS, Davila E, Kardinal CG, Laufman L, Pierce HI, Abramson N, Keller AM, Hamm JT, Wickerham DL, Begovic M, Tan-Chiu E, Tian W, Wolmark N (1999) Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 17(11):3374\u20133388","journal-title":"J Clin Oncol"},{"issue":"24","key":"4599_CR5","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1200\/JCO.2010.32.5910","volume":"29","author":"DA Berry","year":"2011","unstructured":"Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes RC, Roche H, Tokuda Y, de Vries EG, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T (2011) High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 29(24):3214\u20133223. \n                        https:\/\/doi.org\/10.1200\/JCO.2010.32.5910","journal-title":"J Clin Oncol"},{"issue":"8","key":"4599_CR6","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"ML Citron","year":"2003","unstructured":"Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8):1431\u20131439. \n                        https:\/\/doi.org\/10.1200\/JCO.2003.09.081","journal-title":"J Clin Oncol"},{"issue":"9980","key":"4599_CR7","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/S0140-6736(14)62048-1","volume":"385","author":"L Mastro Del","year":"2015","unstructured":"Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nistico C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F, Gruppo Italiano Mammella I (2015) Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2\u00a0\u00d7\u00a02 factorial, randomised phase 3 trial. Lancet 385(9980):1863\u20131872. \n                        https:\/\/doi.org\/10.1016\/S0140-6736(14)62048-1","journal-title":"Lancet"},{"issue":"26","key":"4599_CR8","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1200\/JCO.2012.48.1275","volume":"31","author":"SM Swain","year":"2013","unstructured":"Swain SM, Tang G, Geyer CE Jr, Rastogi P, Atkins JN, Donnellan PP, Fehrenbacher L, Azar CA, Robidoux A, Polikoff JA, Brufsky AM, Biggs DD, Levine EA, Zapas JL, Provencher L, Northfelt DW, Paik S, Costantino JP, Mamounas EP, Wolmark N (2013) Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol 31(26):3197\u20133204. \n                        https:\/\/doi.org\/10.1200\/JCO.2012.48.1275","journal-title":"J Clin Oncol"},{"issue":"23","key":"4599_CR9","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1093\/jnci\/dji398","volume":"97","author":"M Venturini","year":"2005","unstructured":"Venturini M, Del Mastro L, Aitini E, Baldini E, Caroti C, Contu A, Testore F, Brema F, Pronzato P, Cavazzini G, Sertoli MR, Canavese G, Rosso R, Bruzzi P (2005) Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 97(23):1724\u20131733. \n                        https:\/\/doi.org\/10.1093\/jnci\/dji398","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"4599_CR10","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1200\/JCO.2009.24.7643","volume":"28","author":"V Moebus","year":"2010","unstructured":"Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Kreienberg R, Konecny GE, Untch M (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28(17):2874\u20132880. \n                        https:\/\/doi.org\/10.1200\/JCO.2009.24.7643","journal-title":"J Clin Oncol"},{"issue":"2","key":"4599_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10549-015-3405-4","volume":"151","author":"F Petrelli","year":"2015","unstructured":"Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, Barni S (2015) Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat 151(2):251\u2013259. \n                        https:\/\/doi.org\/10.1007\/s10549-015-3405-4","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"4599_CR12","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.1998.16.7.2299","volume":"16","author":"HP Gurney","year":"1998","unstructured":"Gurney HP, Ackland S, Gebski V, Farrell G (1998) Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 16(7):2299\u20132304","journal-title":"J Clin Oncol"},{"issue":"2","key":"4599_CR13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/bjc.1997.49","volume":"75","author":"T Saarto","year":"1997","unstructured":"Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I (1997) Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75(2):301\u2013305","journal-title":"Br J Cancer"},{"issue":"11","key":"4599_CR14","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0959-8049(98)00209-3","volume":"34","author":"M Colleoni","year":"1998","unstructured":"Colleoni M, Price K, Castiglione-Gertsch M, Goldhirsch A, Coates A, Lindtner J, Collins J, Gelber RD, Thurlimann B, Rudenstam CM (1998) Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. Eur J Cancer 34(11):1693\u20131700","journal-title":"Eur J Cancer"},{"issue":"11","key":"4599_CR15","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/sj.bjc.6690594","volume":"80","author":"P Poikonen","year":"1999","unstructured":"Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C (1999) Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 80(11):1763\u20131766. \n                        https:\/\/doi.org\/10.1038\/sj.bjc.6690594","journal-title":"Br J Cancer"},{"issue":"10","key":"4599_CR16","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1038\/sj.bjc.6601366","volume":"89","author":"DA Cameron","year":"2003","unstructured":"Cameron DA, Massie C, Kerr G, Leonard RC (2003) Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89(10):1837\u20131842. \n                        https:\/\/doi.org\/10.1038\/sj.bjc.6601366","journal-title":"Br J Cancer"},{"key":"4599_CR17","unstructured":"Paridaens R, Wildiers J, Dumez H, Thomas J, Weltens C, Van den Bogaert W, Van Limbergen E, Aerts R, Kauffmann L, Van OOsterom A (2002) Impact of dose-intensity of adjuvant CMF on disease-free (DFS) and overall survival (OS) in breast cancer (BC): A retrospective analysis. Abstract 161. Paper presented at the European Society for Medical Oncology Annual Meeting, Nice, France"},{"issue":"1","key":"4599_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3109\/0284186X.2010.535847","volume":"50","author":"S Margolin","year":"2011","unstructured":"Margolin S, Bengtsson NO, Carlsson L, Edlund P, Hellstrom M, Karlsson P, Lidbrink E, Linderholm B, Lindman H, Malmstrom P, Pettersson Skold D, Soderberg M, Villman K, Bergh J, Scandinavian Breast Group Study SBG (2011) A randomised feasibility\/phase II study (SBG 2004-1) with dose-dense\/tailored epirubicin, cyclophosphamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC\/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. Acta Oncol 50(1):35\u201341. \n                        https:\/\/doi.org\/10.3109\/0284186X.2010.535847","journal-title":"Acta Oncol"},{"issue":"4","key":"4599_CR19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1200\/JCO.2013.54.6119","volume":"33","author":"AC Wolff","year":"2015","unstructured":"Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE (2015) Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J Clin Oncol 33(4):340\u2013348. \n                        https:\/\/doi.org\/10.1200\/JCO.2013.54.6119","journal-title":"J Clin Oncol"},{"issue":"2","key":"4599_CR20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/oxfordjournals.annonc.a058121","volume":"3","author":"MJ Ratain","year":"1992","unstructured":"Ratain MJ, Rowley JD (1992) Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol 3(2):107\u2013111","journal-title":"Ann Oncol"},{"issue":"12","key":"4599_CR21","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1986.4.12.1748","volume":"4","author":"HM Kantarjian","year":"1986","unstructured":"Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ (1986) Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 4(12):1748\u20131757","journal-title":"J Clin Oncol"},{"issue":"7","key":"4599_CR22","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","volume":"117","author":"S Kayser","year":"2011","unstructured":"Kayser S, Dohner K, Krauter J, Kohne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Kundgen A, Gotze K, Rummel M, Nachbaur D, Schlegelberger B, Gohring G, Spath D, Morlok C, Zucknick M, Ganser A, Dohner H, Schlenk RF, German-Austrian A (2011) The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117(7):2137\u20132145. \n                        https:\/\/doi.org\/10.1182\/blood-2010-08-301713","journal-title":"Blood"},{"issue":"4","key":"4599_CR23","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/annonc\/mdl488","volume":"18","author":"N Wilking","year":"2007","unstructured":"Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Bergh J (2007) Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol 18(4):694\u2013700. \n                        https:\/\/doi.org\/10.1093\/annonc\/mdl488","journal-title":"Ann Oncol"},{"issue":"22","key":"4599_CR24","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.1200\/JCO.2005.09.423","volume":"23","author":"MN Levine","year":"2005","unstructured":"Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N, National CancerInstituteof Canada Clinical Trials Group (2005) Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 23(22):5166\u20135170. \n                        https:\/\/doi.org\/10.1200\/JCO.2005.09.423","journal-title":"J Clin Oncol"},{"issue":"18","key":"4599_CR25","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1200\/JCO.2005.05.029","volume":"23","author":"C Praga","year":"2005","unstructured":"Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbrat P, Hery M, Nilsson J, Onida F, Piccart M, Shepherd L, Therasse P, Wils J, Rogers D (2005) Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 23(18):4179\u20134191. \n                        https:\/\/doi.org\/10.1200\/JCO.2005.05.029","journal-title":"J Clin Oncol"},{"issue":"6","key":"4599_CR26","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S1470-2045(11)70094-8","volume":"12","author":"H Bonnefoi","year":"2011","unstructured":"Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, Andre S, Litiere S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R, Investigators EBS (2011) TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994\/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 12(6):527\u2013539. \n                        https:\/\/doi.org\/10.1016\/S1470-2045(11)70094-8","journal-title":"Lancet Oncol"},{"issue":"18","key":"4599_CR27","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2016.15865","volume":"316","author":"T Foukakis","year":"2016","unstructured":"Foukakis T, von Minckwitz G, Bengtsson NO, Brandberg Y, Wallberg B, Fornander T, Mlineritsch B, Schmatloch S, Singer CF, Steger G, Egle D, Karlsson E, Carlsson L, Loibl S, Untch M, Hellstrom M, Johansson H, Anderson H, Malmstrom P, Gnant M, Greil R, Mobus V, Bergh J, Swedish Breast Cancer Group tGBG, the Austrian B, Colorectal Cancer Study G (2016) Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: a Randomized Clinical Trial. JAMA 316(18):1888\u20131896. \n                        https:\/\/doi.org\/10.1001\/jama.2016.15865","journal-title":"JAMA"},{"issue":"36","key":"4599_CR28","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","volume":"24","author":"H Roche","year":"2006","unstructured":"Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulie P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Geneve J, Asselain B (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24(36):5664\u20135671. \n                        https:\/\/doi.org\/10.1200\/JCO.2006.07.3916","journal-title":"J Clin Oncol"},{"issue":"8","key":"4599_CR29","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/ncponc0560","volume":"3","author":"R Simon","year":"2006","unstructured":"Simon R, Norton L (2006) The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol 3(8):406\u2013407. \n                        https:\/\/doi.org\/10.1038\/ncponc0560","journal-title":"Nat Clin Pract Oncol"},{"issue":"12","key":"4599_CR30","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1200\/JCO.1986.4.12.1827","volume":"4","author":"DD Hoff Von","year":"1986","unstructured":"Von Hoff DD, Clark GM, Weiss GR, Marshall MH, Buchok JB, Knight WA 3rd, LeMaistre CF (1986) Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens. J Clin Oncol 4(12):1827\u20131834","journal-title":"J Clin Oncol"},{"key":"4599_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejca.2016.08.010","volume":"68","author":"T Price","year":"2016","unstructured":"Price T, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Guan X, Peeters M (2016) Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. Eur J Cancer 68:51\u201359. \n                        https:\/\/doi.org\/10.1016\/j.ejca.2016.08.010","journal-title":"Eur J Cancer"},{"key":"4599_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.breast.2016.02.010","volume":"27","author":"PE Liedke","year":"2016","unstructured":"Liedke PE, Tu D, Shepherd L, Chavarri-Guerra Y, Pritchard KI, Stearns V, Goss PE (2016) New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole\u2014Analyses from NCIC CTG MA.17. Breast 27:99\u2013104. \n                        https:\/\/doi.org\/10.1016\/j.breast.2016.02.010","journal-title":"Breast"},{"issue":"12","key":"4599_CR33","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S1470-2045(08)70259-6","volume":"9","author":"Cuzick J, Sestak I, Cella D, Fallowfield L, Group AT","year":"2008","unstructured":"Cuzick J, Sestak I, Cella D, Fallowfield L, Group AT (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9(12):1143\u20131148. \n                        https:\/\/doi.org\/10.1016\/S1470-2045(08)70259-6","journal-title":"Lancet Oncol"},{"issue":"3","key":"4599_CR34","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/annonc\/mdv595","volume":"27","author":"HS Rugo","year":"2016","unstructured":"Rugo HS, Hortobagyi GN, Yao J, Pavel M, Ravaud A, Franz D, Ringeisen F, Gallo J, Rouyrre N, Anak O, Motzer R (2016) Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol 27(3):519\u2013525. \n                        https:\/\/doi.org\/10.1093\/annonc\/mdv595","journal-title":"Ann Oncol"},{"issue":"11","key":"4599_CR35","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1158\/1078-0432.CCR-10-2806","volume":"17","author":"BI Rini","year":"2011","unstructured":"Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Bair AH, Ricart AD, Olszanski AJ, Letrent KJ, Kim S, Rixe O (2011) Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 17(11):3841\u20133849. \n                        https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2806","journal-title":"Clin Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-017-4599-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4599-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4599-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T07:56:31Z","timestamp":1520236591000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-017-4599-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,30]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["4599"],"URL":"https:\/\/doi.org\/10.1007\/s10549-017-4599-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2017,11,30]]}}}